Monopar Therapeutics (NASDAQ:MNPR) Earns Overweight Rating from Analysts at Piper Sandler

Research analysts at Piper Sandler began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research note issued on Friday, MarketBeat.com reports. The firm set an "overweight" rating and a $72.00 price target on the stock. Piper Sandler's price target would suggest a potential upside of 184.02% from the company's current price.

Several other brokerages also recently weighed in on MNPR. HC Wainwright raised their price target on Monopar Therapeutics from $6.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $50.00 target price on the stock.

Monopar Therapeutics Stock Up 3.6 %

MNPR stock traded up $0.89 during mid-day trading on Friday, hitting $25.35. 38,652 shares of the company were exchanged, compared to its average volume of 36,692. The firm has a market capitalization of $133.80 million, a P/E ratio of -12.87 and a beta of 1.23. The business has a fifty day simple moving average of $21.84 and a 200-day simple moving average of $10.70. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. Research analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company's stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $16.25 per share, with a total value of $25,187.50. Following the purchase, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.